6ZGC
Crystal structure of the ACVR1 (ALK2) kinase in complex with the compound Saracatinib (AZD0530)
Summary for 6ZGC
Entry DOI | 10.2210/pdb6zgc/pdb |
Descriptor | Activin receptor type I, N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE, POTASSIUM ION, ... (5 entities in total) |
Functional Keywords | inhibitor complex. kinase. type i receptor, bmp, signalling., signaling protein |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 4 |
Total formula weight | 141994.56 |
Authors | Williams, E.P.,Galan Bartual, S.,Burgess-Brown, N.,von Delft, F.,Arrowsmith, C.H.,Edwards, A.M.,Bountra, C.,Bullock, A.N. (deposition date: 2020-06-18, release date: 2020-07-29, Last modification date: 2024-01-24) |
Primary citation | Williams, E.,Bagarova, J.,Kerr, G.,Xia, D.D.,Place, E.S.,Dey, D.,Shen, Y.,Bocobo, G.A.,Mohedas, A.H.,Huang, X.,Sanderson, P.E.,Lee, A.,Zheng, W.,Economides, A.N.,Smith, J.C.,Yu, P.B.,Bullock, A.N. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight, 6:-, 2021 Cited by PubMed: 33705358DOI: 10.1172/jci.insight.95042 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.67 Å) |
Structure validation
Download full validation report